Cargando…

Peptide P5 (residues 628–683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection

The membrane proximal region (MPR) of the transmembrane subunit, gp41, of the HIV envelope glycoprotein plays a critical role in HIV-1 infection of CD4(+) target cells and CD4-independent mucosal entry. It contains continuous epitopes recognized by neutralizing IgG antibodies 2F5, 4E10 and Z13, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Huifeng, Tudor, Daniela, Alfsen, Annette, Labrosse, Beatrice, Clavel, François, Bomsel, Morgane
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585100/ https://www.ncbi.nlm.nih.gov/pubmed/18925934 http://dx.doi.org/10.1186/1742-4690-5-93

Ejemplares similares

The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity
por: Xu, Lin, et al.
Publicado: (2021)

Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41
por: Duchemin, Maxence, et al.
Publicado: (2020)

IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis
por: Duchemin, Maxence, et al.
Publicado: (2018)

The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals
por: Khamassi, Marwa, et al.
Publicado: (2020)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

P11-20. HIV-1 gp41-specific mucosal IgAs from highly exposed but IgG seronegative women block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection
por: Tudor, D, et al.
Publicado: (2009)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
por: Leroux-Roels, Geert, et al.
Publicado: (2013)

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-120 interface
por: Huang, Jinghe, et al.
Publicado: (2014)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

Entry of viruses through the epithelial barrier: pathogenic trickery
por: Bomsel, Morgane, et al.
Publicado: (2003)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes
por: Strokappe, Nika M., et al.
Publicado: (2019)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?
por: Teixeira, Cátia, et al.
Publicado: (2016)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41
por: Blish, Catherine A, et al.
Publicado: (2008)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity
por: Yang, Zheng, et al.
Publicado: (2018)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

Modulation of Cytokine Release and Gene Expression by the Immunosuppressive Domain of gp41 of HIV-1
por: Denner, Joachim, et al.
Publicado: (2013)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
por: Khasnis, Mukta D., et al.
Publicado: (2016)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
por: Caillat, Christophe, et al.
Publicado: (2021)

HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies
por: Wang, Ji, et al.
Publicado: (2011)

Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41
por: Pu, Jing, et al.
Publicado: (2019)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
por: Wang, Xinling, et al.
Publicado: (2021)

Alpha-1-antitrypsin interacts with gp41 to block HIV-1 entry into CD4+ T lymphocytes
por: Zhou, Xueyuan, et al.
Publicado: (2016)

Mutational analysis of HIV-1 gp41 mediated apoptosis and its correlation with fusion/hemifusion
por: Garg, Himanshu, et al.
Publicado: (2006)

Viroporin potential of the lentivirus lytic peptide (LLP) domains of the HIV-1 gp41 protein
por: Costin, Joshua M, et al.
Publicado: (2007)

Soluble and bacteriophage T4 displayed gp41 mutant proteins as HIV-1 vaccine candidates
por: Gao, G, et al.
Publicado: (2012)

Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
por: Frey, Gary, et al.
Publicado: (2010)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike
por: Lee, Jeong Hyun, et al.
Publicado: (2015)

Cytotoxicity of HIV-gp41 segments expressed inE. coli
por: Yuan, Yuhua, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_rfb4surbfvods27muu3qhavdo7